Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066308 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol for Reduction of Brain Neuroinflammation
A Phase 2 study of Depressive Symptoms and Back Pain, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05066308: Recruiting Phase 2 study of Depressive Symptoms and Back Pain, sponsored by Massachusetts General Hospital.
NCT05066308 is a Phase 2 study of Depressive Symptoms and Back Pain that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 260-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05066308, a Phase 2 study of Depressive Symptoms and Back Pain, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
Primary Outcome
The investigators will test for the presence of a significant treatment effect in the brain \[11C\]PBR28 signal in the thalamus, in order to test whether patients in the CBD arm will demonstrate significantly larger treatment-related reductions in neuroinflammation, compared to patients in the placebo arm.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBD
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
What NCT05066308 shows while recruiting
NCT05066308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 260-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Depressive Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05066308 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05066308 about?
NCT05066308 is a clinical study titled "Cannabidiol for Reduction of Brain Neuroinflammation". This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
What is the current status of trial NCT05066308?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-01-04. Estimated completion is 2026-12-15.
What conditions does trial NCT05066308 study?
This clinical trial studies the following conditions: Depressive Symptoms, Back Pain.
What interventions are being tested in trial NCT05066308?
The interventions under investigation include: Placebo (OTHER), CBD (DRUG).
Who is sponsoring clinical trial NCT05066308?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05066308 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05066308's enrollment target sits among peer trials
80 35th of 60 higher than 24 of 60 other Depressive Symptoms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
ACTIVE NOT RECRUITING · Phase 2
-
Beating the Blues for Your Heart
COMPLETED · Phase 2
-
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
COMPLETED · Phase 2
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Caregiver Stress and Sleep Study
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI